Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
780 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00476086 | Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus | completed | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 24, 2018 | clinicaltrials |
| NCT00768144 | Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma | completed | Phase 2 | 36 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 24, 2018 | clinicaltrials |
| NCT00782626 | Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas | completed | Phase 2 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 15, 2018 | clinicaltrials |
| NCT03227432 | An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 14, 2018 | clinicaltrials |
| NCT00230542 | Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer | completed | Phase 2 | 44 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 13, 2018 | clinicaltrials |
| NCT00268918 | Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients | completed | Phase 1 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 27, 2018 | clinicaltrials |
| NCT00520013 | Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors | completed | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 27, 2018 | clinicaltrials |
| NCT00525460 | Young Women Diagnosed With Early Stage Ovarian Cancer: A Focus on Fertility Issues and Sexual Function | completed | — | 16 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 27, 2018 | clinicaltrials |
| NCT02478164 | Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma | completed | Phase 2 | 17 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 24, 2018 | clinicaltrials |
| NCT00458549 | Polyunsaturated Fatty Acids in Treating Patients With Prostate Cancer Undergoing Prostate Biopsy and/or Surgery | terminated | N/A | 232 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 13, 2018 | clinicaltrials |
| NCT02135211 | Healthy Directions After Lung Surgery Pilot | completed | N/A | 42 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT00165399 | Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment | completed | Phase 2 | 62 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 25, 2018 | clinicaltrials |
| NCT01340300 | Exercise and Metformin in Colorectal and Breast Cancer Survivors | completed | Phase 2 | 139 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 6, 2018 | clinicaltrials |
| NCT02423148 | Pilot Study of Novel Fluorescence Endoscopic Device for Sentinel Lymph Node Mapping in Lung Cancer | withdrawn | N/A | 0 | Dana-Farber Cancer InstituteOTHER | 0 | May 16, 2018 | clinicaltrials |
| NCT00889187 | Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT00090857 | Letrozole in Preventing Breast Cancer in Postmenopausal Women(WISE) | completed | Phase 2 | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 30, 2018 | clinicaltrials |
| NCT00052611 | Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia | completed | Phase 2 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 29, 2018 | clinicaltrials |
| NCT00095901 | Capecitabine For Nasopharyngeal Cancer | completed | Phase 2 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 29, 2018 | clinicaltrials |
| NCT01024387 | AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 8, 2018 | clinicaltrials |
| NCT00797732 | A Pilot Study of Acupuncture Treatment for Dysphagia | completed | N/A | 42 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 13, 2018 | clinicaltrials |
| NCT00852852 | Computerized Assessment for Patients With Cancer(ESRA-C_II) | completed | N/A | 779 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 1, 2018 | clinicaltrials |
| NCT02261649 | Impact of Cerebellar Mass Resection on Pain Processing | completed | — | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 1, 2018 | clinicaltrials |
| NCT01844999 | Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks | completed | N/A | 392 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 31, 2018 | clinicaltrials |
| NCT01472627 | Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro | completed | — | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 11, 2018 | clinicaltrials |
| NCT00422656 | Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia | completed | Phase 2 | 37 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 26, 2017 | clinicaltrials |
| NCT00098514 | Talotrexin in Treating Patients With Advanced or Recurrent Solid Tumors | completed | Phase 1 | 53 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 18, 2017 | clinicaltrials |
| NCT00630344 | RAD001 and Bicalutamide for Androgen Independent Prostate Cancer | completed | Phase 2 | 36 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 8, 2017 | clinicaltrials |
| NCT01221753 | Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study | terminated | Phase 2 | 7 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT01808417 | NIR-Guided Sentinel Lymph-Node Mapping for Esophageal Cancer | completed | Phase 1 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT02752009 | Evaluation Of Lymph Nodes After Neoadjuvant Chemotherapy | withdrawn | N/A | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Nov 21, 2017 | clinicaltrials |
| NCT00570674 | Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck | terminated | Phase 1 / Phase 2 | 29 | Dana-Farber Cancer InstituteOTHER | 0 | Nov 13, 2017 | clinicaltrials |
| NCT00137852 | Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer | completed | Phase 2 | 35 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 20, 2017 | clinicaltrials |
| NCT02666209 | Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma | no longer available | — | — | Dana-Farber Cancer InstituteOTHER | 1 | Aug 28, 2017 | clinicaltrials |
| NCT00394433 | Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer | completed | Phase 2 | 38 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT00005096 | Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer | completed | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 14, 2017 | clinicaltrials |
| NCT00047281 | Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma | completed | Phase 2 | — | Dana-Farber Cancer InstituteOTHER | 1 | Jul 11, 2017 | clinicaltrials |
| NCT00047294 | Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | — | Dana-Farber Cancer InstituteOTHER | 1 | Jul 11, 2017 | clinicaltrials |
| NCT02658396 | GO-203-2C + Bortezomib For Relapsed Or Refractory MM | withdrawn | Phase 1 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 5, 2017 | clinicaltrials |
| NCT01290263 | Amgen 386 for Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00020670 | Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia | terminated | Early Phase 1 | 9 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 20, 2017 | clinicaltrials |
| NCT00006107 | Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer | completed | Phase 1 | 31 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 16, 2017 | clinicaltrials |
| NCT01273805 | Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT00165243 | Tangential Radiation Therapy Without Axillary Dissection in Breast Cancer | completed | Phase 2 | 100 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 7, 2017 | clinicaltrials |
| NCT01972516 | Tivozanib As Maintenance Therapy In GYN | terminated | Phase 2 | 4 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 5, 2017 | clinicaltrials |
| NCT01323920 | Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors | completed | Phase 2 | 35 | Dana-Farber Cancer InstituteOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT00658697 | Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer | completed | Phase 2 | 42 | Dana-Farber Cancer InstituteOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT01243619 | FLT PET/CT for Staging, Target Definition and Assessment of Response to Therapy in Patients With Esophageal Cancer | completed | N/A | 5 | Dana-Farber Cancer InstituteOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT00003045 | Hyperthermia Plus Radiation Therapy in Treating Patients With Nonmetastatic Advanced Prostate Cancer | completed | N/A | 38 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 26, 2017 | clinicaltrials |
| NCT00004070 | Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer | completed | Phase 1 / Phase 2 | 7 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 20, 2017 | clinicaltrials |
| NCT00004163 | Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer | completed | Phase 2 | 14 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 18, 2017 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials